Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 672838, 16 pages
http://dx.doi.org/10.1155/2015/672838
Review Article

Dietary Factors in the Etiology of Parkinson’s Disease

School of Health Sciences, Purdue University, 550 Stadium Mall Dr., West Lafayette, IN 47907, USA

Received 9 May 2014; Revised 7 November 2014; Accepted 8 November 2014

Academic Editor: Tan Eng King

Copyright © 2015 Zeynep S. Agim and Jason R. Cannon. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. B. Singleton, M. J. Farrer, and V. Bonifati, “The genetics of Parkinson's disease: progress and therapeutic implications,” Movement Disorders, vol. 28, no. 1, pp. 14–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. R. Cannon and J. T. Greenamyre, “The role of environmental exposures in neurodegeneration and neurodegenerative diseases,” Toxicological Sciences, vol. 124, no. 2, pp. 225–250, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Cannon and J. T. Greenamyre, “Neurotoxic in vivo models of Parkinson's disease: recent advances,” Progress in Brain Research, vol. 184, pp. 17–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. T. Allen and L. S. Levy, “Parkinsons disease and pesticide exposure—a new assessment,” Critical Reviews in Toxicology, vol. 43, no. 6, pp. 515–534, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Moretto and C. Colosio, “The role of pesticide exposure in the genesis of Parkinson's disease: epidemiological studies and experimental data,” Toxicology, vol. 307, pp. 24–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Ono and M. Yamada, “Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: Implications for Lewy body diseases,” Neurobiology of Disease, vol. 25, no. 2, pp. 446–454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Logroscino, K. Marder, L. Cote, M.-X. Tang, S. Shea, and R. Mayeux, “Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study,” Annals of Neurology, vol. 39, no. 1, pp. 89–94, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. S. M. Zhang, M. A. Hernán, H. Chen, D. Spiegelman, W. C. Willett, and A. Ascherio, “Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk,” Neurology, vol. 59, no. 8, pp. 1161–1169, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. R. D. Abbott, G. W. Ross, L. R. White et al., “Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia aging study,” Journal of Neurology, vol. 250, supplement 3, pp. III30–III39, 2003. View at Google Scholar · View at Scopus
  10. M. Etminan, S. S. Gill, and A. Samii, “Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis,” The Lancet Neurology, vol. 4, no. 6, pp. 362–365, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Miyake, W. Fukushima, K. Tanaka et al., “Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan,” European Journal of Neurology, vol. 18, no. 1, pp. 106–113, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Koushik, D. J. Hunter, D. Spiegelman et al., “Intake of the major carotenoids and the risk of epithelial ovarian cancer in a pooled analysis of 10 cohort studies,” International Journal of Cancer, vol. 119, no. 9, pp. 2148–2154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. D. Finkelstein, “Methionine metabolism in mammals,” Journal of Nutritional Biochemistry, vol. 1, no. 5, pp. 228–237, 1990. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Scott and D. G. Weir, “Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry,” Journal of Cardiovascular Risk, vol. 5, no. 4, pp. 223–227, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Duan, B. Ladenheim, R. G. Cutler, I. I. Kruman, J. L. Cadet, and M. P. Mattson, “Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease,” Journal of Neurochemistry, vol. 80, no. 1, pp. 101–110, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. I. I. Kruman, C. Culmsee, S. L. Chan et al., “Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity,” The Journal of Neuroscience, vol. 20, no. 18, pp. 6920–6926, 2000. View at Google Scholar · View at Scopus
  17. I. I. Kruman, T. S. Kumaravel, A. Lohani et al., “Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease,” Journal of Neuroscience, vol. 22, no. 5, pp. 1752–1762, 2002. View at Google Scholar · View at Scopus
  18. D. A. Adelekan and D. I. Thurnham, “Effects of combined riboflavin and iron deficiency on the hematological status and tissue iron concentrations of the rat,” Journal of Nutrition, vol. 116, no. 7, pp. 1257–1265, 1986. View at Google Scholar · View at Scopus
  19. H. J. Powers, L. T. Weaver, S. Austin, A. J. A. Wright, and S. J. Fairweather-Tait, “Riboflavin deficiency in the rat: effects on iron utilization and loss,” British Journal of Nutrition, vol. 65, no. 3, pp. 487–496, 1991. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Hellenbrand, H. Boeing, B.-P. Robra et al., “Diet and Parkinson's disease II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study,” Neurology, vol. 47, no. 3, pp. 644–650, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. L. M. L. De Lau, M. Bornebroek, J. C. M. Witteman, A. Hofman, P. J. Koudstaal, and M. M. B. Breteler, “Dietary fatty acids and the risk of Parkinson disease: the rotterdam study,” Neurology, vol. 64, no. 12, pp. 2040–2045, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Murakami, Y. Miyake, S. Sasaki et al., “Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case-control study in Japan,” British Journal of Nutrition, vol. 104, no. 5, pp. 757–764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. G. Coimbra and V. B. C. Junqueira, “High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients,” Brazilian Journal of Medical and Biological Research, vol. 36, no. 10, pp. 1409–1417, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Chen, S. M. Zhang, M. A. Schwarzschild et al., “Folate intake and risk of Parkinson's disease,” The American Journal of Epidemiology, vol. 160, no. 4, pp. 368–375, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. C. C. Johnson, J. M. Gorell, B. A. Rybicki, K. Sanders, and E. L. Peterson, “Adult nutrient intake as a risk factor for Parkinson's disease,” International Journal of Epidemiology, vol. 28, no. 6, pp. 1102–1109, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Seitz, S. Gebhardt, J. F. Beck et al., “Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene expression in the human neuroblastoma cell line SK-N-SH,” Neuroscience Letters, vol. 244, no. 1, pp. 33–36, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. M. E. Rice, “Ascorbate regulation and its neuroprotective role in the brain,” Trends in Neurosciences, vol. 23, no. 5, pp. 209–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Ghani, D. Stevens, J. Weiss, and R. Rosenbaum, “Vitamins and the risk for Parkinson's disease,” Neurology, vol. 59, no. 8, pp. E8–E9, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. D. W. Eyles, S. Smith, R. Kinobe, M. Hewison, and J. J. McGrath, “Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain,” Journal of Chemical Neuroanatomy, vol. 29, no. 1, pp. 21–30, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. J.-F. Chabas, D. Stephan, T. Marqueste et al., “Cholecalciferol (Vitamin D3) improves myelination and recovery after nerve injury,” PLoS ONE, vol. 8, no. 5, Article ID e65034, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Shinpo, S. Kikuchi, H. Sasaki, F. Moriwaka, and K. Tashiro, “Effect of 1,25-dihydroxyvitamin D(3) on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4-phenylpyridine,” Journal of Neuroscience Research, vol. 62, no. 3, pp. 374–382, 2000. View at Google Scholar
  32. J.-Y. Wang, J.-N. Wu, T.-L. Cherng et al., “Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats,” Brain Research, vol. 904, no. 1, pp. 67–75, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Sato, M. Kikuyama, and K. Oizumi, “High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease,” Neurology, vol. 49, no. 5, pp. 1273–1278, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Sato, M. Kaji, T. Tsuru, and K. Oizumi, “Risk factors for hip fracture among elderly patients with Parkinson's disease,” Journal of the Neurological Sciences, vol. 182, no. 2, pp. 89–93, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Derex and P. Trouillas, “Reversible Parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy,” Movement Disorders, vol. 12, no. 4, pp. 612–613, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Lv, H. Qi, L. Wang et al., “Vitamin D status and Parkinson's disease: a systematic review and meta-analysis,” Neurological Sciences, vol. 35, no. 11, p. 173, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. H. L. Newmark and J. Newmark, “Vitamin D and Parkinson's disease: a hypothesis,” Movement Disorders, vol. 22, no. 4, pp. 461–468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. A. L. Peterson, “A review of vitamin D and Parkinson's disease,” Maturitas, vol. 78, no. 1, pp. 40–44, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. W. Butler, A. Burt, T. L. Edwards et al., “Vitamin D receptor gene as a candidate gene for Parkinson disease,” Annals of Human Genetics, vol. 75, no. 2, pp. 201–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Z. Lv, B. Tang, Q. Sun, X. Yan, and J. Guo, “Association study between vitamin D receptor gene polymorphisms and patients with Parkinson disease in Chinese Han population,” International Journal of Neuroscience, vol. 123, no. 1, pp. 60–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. C.-H. Lin, K.-H. Chen, M.-L. Chen, H.-I. Lin, and R.-M. Wu, “Vitamin D receptor genetic variants and Parkinson's disease in a Taiwanese population,” Neurobiology of Aging, vol. 35, no. 5, pp. 1212.e11–1212.e13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Akaneya, M. Takahashi, and H. Hatanaka, “Involvement of free radicals in MPP+ neurotoxicity against rat dopaminergic neurons in culture,” Neuroscience Letters, vol. 193, no. 1, pp. 53–56, 1995. View at Publisher · View at Google Scholar · View at Scopus
  43. D. T. Dexter, D. J. Brooks, A. E. Harding et al., “Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies,” Annals of Neurology, vol. 35, no. 3, pp. 298–303, 1994. View at Publisher · View at Google Scholar · View at Scopus
  44. I. N. Odunze, L. K. Klaidman, and J. D. Adams Jr., “MPTP toxicity in the mouse brain and vitamin E,” Neuroscience Letters, vol. 108, no. 3, pp. 346–349, 1990. View at Publisher · View at Google Scholar · View at Scopus
  45. J. D. Adams Jr., I. N. Odunze, and A. Sevanian, “Induction by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of lipid peroxidation in vivo in vitamin E deficient mice,” Biochemical Pharmacology, vol. 39, no. 1, pp. R5–R8, 1990. View at Publisher · View at Google Scholar · View at Scopus
  46. R. A. Abbott, M. Cox, H. Markus, and A. Tomkins, “Diet, body size and micronutrient status in Parkinson's disease,” European Journal of Clinical Nutrition, vol. 46, no. 12, pp. 879–884, 1992. View at Google Scholar · View at Scopus
  47. L. I. Golbe, T. M. Farrell, and P. H. Davis, “Follow-up study of early-life protective and risk factors in Parkinson's disease,” Movement Disorders, vol. 5, no. 1, pp. 66–70, 1990. View at Publisher · View at Google Scholar · View at Scopus
  48. D. M. Morens, A. Grandinetti, C. I. Waslien, C. B. Park, G. W. Ross, and L. R. White, “Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake,” Neurology, vol. 46, no. 5, pp. 1270–1274, 1996. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Shoulson, S. Fahn, D. Oakes et al., “Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease,” The New England Journal of Medicine, vol. 328, no. 3, pp. 176–183, 1993. View at Publisher · View at Google Scholar · View at Scopus
  50. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids, National Academies Press, Washington, DC, USA, 2000.
  51. C. W. Olanow, “Dietary vitamin E and Parkinson's disease: something to chew on,” The Lancet Neurology, vol. 2, no. 2, p. 74, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. J. P. E. Spencer, “Flavonoids: modulators of brain function?” British Journal of Nutrition, vol. 99, no. E-S1, pp. ES60–ES77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Manach, A. Scalbert, C. Morand, C. Remesy, and L. Jimenez, “Polyphenols: food sources and bioavailability,” The American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 727–747, 2004. View at Google Scholar · View at Scopus
  54. A. L. Waterhouse, J. R. Shirley, and J. L. Donovan, “Antioxidants in chocolate,” The Lancet, vol. 348, no. 9030, p. 834, 1996. View at Google Scholar · View at Scopus
  55. C. Ramassamy, “Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets,” European Journal of Pharmacology, vol. 545, no. 1, pp. 51–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Yabuki, Y. Ohizumi, A. Yokosuka, Y. Mimaki, and K. Fukunaga, “Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced parkinson model mice,” Neuroscience, vol. 259, pp. 126–141, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. K. E. Strathearn, G. G. Yousef, M. H. Grace et al., “Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinsons disease,” Brain Research, vol. 1555, pp. 60–77, 2014. View at Google Scholar
  58. X. Gao, A. Cassidy, M. A. Schwarzschild, E. B. Rimm, and A. Ascherio, “Habitual intake of dietary flavonoids and risk of Parkinson disease,” Neurology, vol. 78, no. 15, pp. 1138–1145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Sääksjärvi, P. Knekt, A. Lundqvist et al., “A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality,” British Journal of Nutrition, vol. 109, no. 2, pp. 329–337, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. K. A. Youdim, M. Z. Qaiser, D. J. Begley, C. A. Rice-Evans, and N. J. Abbott, “Flavonoid permeability across an in situ model of the blood-brain barrier,” Free Radical Biology and Medicine, vol. 36, no. 5, pp. 592–604, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. J. A. Mattison, M. A. Lane, G. S. Roth, and D. K. Ingram, “Calorie restriction in rhesus monkeys,” Experimental Gerontology, vol. 38, no. 1-2, pp. 35–46, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Weindruch and R. S. Sohal, “Caloric intake and aging,” The New England Journal of Medicine, vol. 337, no. 14, pp. 986–994, 1997. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Wanagat, D. B. Allison, and R. Weindruch, “Caloric intake and aging: mechanisms in rodents and a study in nonhuman primates,” Toxicological Sciences, vol. 52, no. 2, supplement, pp. 35–40, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. G. S. Roth and J. A. Joseph, “Cellular and molecular mechanisms of impaired dopaminergic function during aging,” Annals of the New York Academy of Sciences, vol. 719, pp. 129–135, 1994. View at Publisher · View at Google Scholar · View at Scopus
  65. A. J. Bruce-Keller, G. Umberger, R. McFall, and M. P. Mattson, “Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults,” Annals of Neurology, vol. 45, no. 1, pp. 8–15, 1999. View at Google Scholar
  66. J. Lee, K. B. Seroogy, and M. P. Mattson, “Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice,” Journal of Neurochemistry, vol. 80, no. 3, pp. 539–547, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. W. Duan, Z. Guo, and M. P. Mattson, “Brain-derived neurotrophic factor mediates an excitoprotective effect of dietary restriction in mice,” Journal of Neurochemistry, vol. 76, no. 2, pp. 619–626, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. M. P. Mattson, “Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders,” NeuroMolecular Medicine, vol. 3, no. 2, pp. 65–94, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. W. Duan and M. P. Mattson, “Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease,” Journal of Neuroscience Research, vol. 57, no. 2, pp. 195–206, 1999. View at Publisher · View at Google Scholar
  70. Z. F. Yu and M. P. Mattson, “Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism,” Journal of Neuroscience Research, vol. 57, no. 6, pp. 830–839, 1999. View at Google Scholar
  71. P. Jadiya, M. Chatterjee, S. R. Sammi, S. Kaur, G. Palit, and A. Nazir, “Sir-2.1 modulates “calorie-restriction-mediated” prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease,” Biochemical and Biophysical Research Communications, vol. 413, no. 2, pp. 306–310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. M. T. Armentero, G. Levandis, P. Bramanti, G. Nappi, and F. Blandini, “Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease,” Experimental Neurology, vol. 212, no. 2, pp. 548–551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. N. Maswood, J. Young, E. Tilmont et al., “Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 52, pp. 18171–18176, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. M. P. Mattson, “Will caloric restriction and folate protect against AD and PD?” Neurology, vol. 60, no. 4, pp. 690–695, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. M. A. Hernán, B. Takkouche, F. Caamaño-Isorna, and J. J. Gestal-Otero, “A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease,” Annals of Neurology, vol. 52, no. 3, pp. 276–284, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. G. W. Ross, R. D. Abbott, H. Petrovitch, L. R. White, and C. M. Tanner, “Relationship between caffeine intake and Parkinson disease,” Journal of American Medical Association, vol. 284, no. 11, pp. 1378–1379, 2000. View at Google Scholar
  77. A. Kyrozis, A. Ghika, P. Stathopoulos, D. Vassilopoulos, D. Trichopoulos, and A. Trichopoulou, “Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece,” European Journal of Epidemiology, vol. 28, no. 1, pp. 67–77, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Popoli, M. G. Caporali, and A. S. de Carolis, “Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motility,” Journal of Pharmacy and Pharmacology, vol. 43, no. 4, pp. 280–281, 1991. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Kanda, T. Tashiro, Y. Kuwana, and P. Jenner, “Adenosine A2A receptors modify motor function in MPTP-treated common marmosets,” NeuroReport, vol. 9, no. 12, pp. 2857–2860, 1998. View at Publisher · View at Google Scholar · View at Scopus
  80. P. J. Richardson, H. Kase, and P. G. Jenner, “Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease,” Trends in Pharmacological Sciences, vol. 18, no. 9, pp. 338–344, 1997. View at Publisher · View at Google Scholar · View at Scopus
  81. J. F. Chen, K. Xu, J. P. Petzer et al., “Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease,” The Journal of Neuroscience, vol. 21, no. 10, Article ID RC143, 2001. View at Google Scholar · View at Scopus
  82. A. Nehlig, J.-L. Daval, and G. Debry, “Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects,” Brain Research Reviews, vol. 17, no. 2, pp. 139–170, 1992. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Ascherio, S. M. Zhang, M. A. Hernán et al., “Prospective study of caffeine consumption and risk of Parkinson's disease in men and women,” Annals of Neurology, vol. 50, no. 1, pp. 56–63, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Ascherio, M. G. Weisskopf, E. J. O'Reilly et al., “Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen,” American Journal of Epidemiology, vol. 160, no. 10, pp. 977–984, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Grandinetti, D. M. Morens, D. Reed, and D. MacEachern, “Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease,” American Journal of Epidemiology, vol. 139, no. 12, pp. 1129–1138, 1994. View at Google Scholar · View at Scopus
  86. G. W. Ross, R. D. Abbott, H. Petrovitch et al., “Association of coffee and caffeine intake with the risk of Parkinson disease,” The Journal of the American Medical Association, vol. 283, no. 20, pp. 2674–2679, 2000. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Liu, X. Guo, Y. Park et al., “Caffeine intake, smoking, and risk of parkinson disease in men and women,” American Journal of Epidemiology, vol. 175, no. 11, pp. 1200–1207, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. L. C. Tan, W.-P. Koh, J.-M. Yuan et al., “Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese health study,” American Journal of Epidemiology, vol. 167, no. 5, pp. 553–560, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. D. K. Y. Chan, J. Woo, S. C. Ho et al., “Genetic and environmental risk factors for Parkinson's disease in a Chinese population,” Journal of Neurology Neurosurgery and Psychiatry, vol. 65, no. 5, pp. 781–784, 1998. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Checkoway, K. Powers, T. Smith-Weller, G. M. Franklin, W. T. Longstreth Jr., and P. D. Swanson, “Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake,” American Journal of Epidemiology, vol. 155, no. 8, pp. 732–738, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. E.-K. Tan, C. Tan, S. M. C. Fook-Chong et al., “Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese,” Journal of the Neurological Sciences, vol. 216, no. 1, pp. 163–167, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. K. M. Powers, D. M. Kay, S. A. Factor et al., “Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk,” Movement Disorders, vol. 23, no. 1, pp. 88–95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. K. Rugbjerg, J. Christensen, A. Tjønneland, and J. H. Olsen, “Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark,” Parkinsonism & Related Disorders, vol. 19, no. 4, pp. 457–460, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. G. Hu, S. Bidel, P. Jousilahti, R. Antikainen, and J. Tuomilehto, “Coffee and tea consumption and the risk of Parkinson's disease,” Movement Disorders, vol. 22, no. 15, pp. 2242–2248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Ascherio, H. Chen, M. A. Schwarzschild, S. M. Zhang, G. A. Colditz, and F. E. Speizer, “Caffeine, postmenopausal estrogen, and risk of Parkinson's disease,” Neurology, vol. 60, no. 5, pp. 790–795, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. H. S. Taylor and J. E. Manson, “Update in hormone therapy use in menopause,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 255–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. R. A. R. Bowen and M. T. Clandinin, “Dietary low linolenic acid compared with docosahexaenoic acid alter synaptic plasma membrane phospholipid fatty acid composition and sodium-potassium ATPase kinetics in developing rats,” Journal of Neurochemistry, vol. 83, no. 4, pp. 764–774, 2002. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Ikemoto, M. Ohishi, Y. Sato et al., “Reversibility of n-3 fatty acid deficiency-induced alterations of learning behavior in the rat: level of n-6 fatty acids as another critical factor,” Journal of Lipid Research, vol. 42, no. 10, pp. 1655–1663, 2001. View at Google Scholar · View at Scopus
  99. B. Levant, M. K. Ozias, and S. E. Carlson, “Specific brain regions of female rats are differentially depleted of docosahexaenoic acid by reproductive activity and an (n-3) fatty acid-deficient diet,” Journal of Nutrition, vol. 137, no. 1, pp. 130–134, 2007. View at Google Scholar · View at Scopus
  100. A. C. Logan, “Omega-3 fatty acids and major depression: a primer for the mental health professional,” Lipids in Health and Disease, vol. 3, article 25, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. T. Moriguchi, R. S. Greiner, and N. Salem Jr., “Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration,” Journal of Neurochemistry, vol. 75, no. 6, pp. 2563–2573, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. A. A. Farooqui, L. A. Horrocks, and T. Farooqui, “Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders,” Chemistry and Physics of Lipids, vol. 106, no. 1, pp. 1–29, 2000. View at Publisher · View at Google Scholar · View at Scopus
  103. K. A. Youdim, A. Martin, and J. A. Joseph, “Essential fatty acids and the brain: possible health implications,” International Journal of Developmental Neuroscience, vol. 18, no. 4-5, pp. 383–399, 2000. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Wu, R. Molteni, Z. Ying, and F. Gomez-Pinilla, “A saturated-fat diet aggravates the outcome of traumatic brain injury on hippocampal plasticity and cognitive function by reducing brain-derived neurotrophic factor,” Neuroscience, vol. 119, no. 2, pp. 365–375, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. F. Calon, G. P. Lim, F. Yang et al., “Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model,” Neuron, vol. 43, no. 5, pp. 633–645, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. V. de Smedt-Peyrusse, F. Sargueil, A. Moranis, H. Harizi, S. Mongrand, and S. Layé, “Docosahexaenoic acid prevents lipopolysaccharide-induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization,” Journal of Neurochemistry, vol. 105, no. 2, pp. 296–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Hashimoto, S. Hossain, T. Shimada et al., “Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats,” Journal of Neurochemistry, vol. 81, no. 5, pp. 1084–1091, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Hashimoto, Y. Tanabe, Y. Fujii, T. Kikuta, H. Shibata, and O. Shido, “Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid β-infused rats,” Journal of Nutrition, vol. 135, no. 3, pp. 549–555, 2005. View at Google Scholar · View at Scopus
  109. A. H. V. Schapira, “Mitochondrial dysfunction in Parkinson's disease,” Cell Death and Differentiation, vol. 14, no. 7, pp. 1261–1266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Wu, Z. Ying, and F. Gomez-Pinilla, “Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats,” Journal of Neurotrauma, vol. 21, no. 10, pp. 1457–1467, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Fernández-Ruiz, I. Lastres-Becker, A. Cabranes, S. González, and J. A. Ramos, “Endocannabinoids and basal ganglia functionality,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 66, no. 2-3, pp. 257–267, 2002. View at Publisher · View at Google Scholar · View at Scopus
  112. A. Giuffrida and D. Piomelli, “The endocannabinoid system: a physiological perspective on its role in psychomotor control,” Chemistry and Physics of Lipids, vol. 108, no. 1-2, pp. 151–158, 2000. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Brodoehl, C. Klingner, G. F. Volk, T. Bitter, O. W. Witte, and C. Redecker, “Decreased olfactory bulb volume in idiopathic Parkinson's disease detected by 3.0-Tesla magnetic resonance imaging,” Movement Disorders, vol. 27, no. 8, pp. 1019–1025, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. P. Liberini, S. Parola, P. F. Spano, and L. Antonini, “Olfaction in Parkinson's disease: methods of assessment and clinical relevance,” Journal of Neurology, vol. 247, no. 2, pp. 88–96, 2000. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Zimmer, S. Vancassel, S. Cantagrel et al., “The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids,” American Journal of Clinical Nutrition, vol. 75, no. 4, pp. 662–667, 2002. View at Google Scholar · View at Scopus
  116. P. Samadi, L. Grégoire, C. Rouillard, P. J. Bédard, T. Di Paolo, and D. Lévesque, “Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys,” Annals of Neurology, vol. 59, no. 2, pp. 282–288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. A. M. Delattre, Á. Kiss, R. E. Szawka et al., “Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease,” Neuroscience Research, vol. 66, no. 3, pp. 256–264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Bousquet, M. Saint-Pierre, C. Julien, N. Salem Jr., F. Cicchetti, and F. Calon, “Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease,” The FASEB Journal, vol. 22, no. 4, pp. 1213–1225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Assayag, E. Yakunin, V. Loeb, D. J. Selkoe, and R. Sharon, “Polyunsaturated fatty acids induce α-synuclein-related pathogenic changes in neuronal cells,” The American Journal of Pathology, vol. 171, no. 6, pp. 2000–2011, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. K. Broersen, D. van den Brink, G. Fraser, M. Goedert, and B. Davletov, “α-synuclein adopts an α-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation,” Biochemistry, vol. 45, no. 51, pp. 15610–15616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. R. Sharon, I. Bar-Joseph, M. P. Frosch, D. M. Walsh, J. A. Hamilton, and D. J. Selkoe, “The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease,” Neuron, vol. 37, no. 4, pp. 583–595, 2003. View at Publisher · View at Google Scholar · View at Scopus
  122. G. Barceló-Coblijn, K. Kitajka, L. G. Puskás et al., “Gene expression and molecular composition of phospholipids in rat brain in relation to dietary n-6 to n-3 fatty acid ratio,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1632, no. 1–3, pp. 72–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. K. Kitajka, A. J. Sinclair, R. S. Weisinger et al., “Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 30, pp. 10931–10936, 2004. View at Publisher · View at Google Scholar · View at Scopus
  124. E. Yakunin, V. Loeb, H. Kisos et al., “α-Synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson's disease,” Brain Pathology, vol. 22, no. 3, pp. 280–294, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. A. J. Bruce-Keller, J. N. Keller, and C. D. Morrison, “Obesity and vulnerability of the CNS,” Biochimica et Biophysica Acta, vol. 1792, no. 5, pp. 395–400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. J. K. Morris, G. L. Bomhoff, J. A. Stanford, and P. C. Geiger, “Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet,” The American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 299, no. 4, pp. R1082–R1090, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. J. K. Morris, G. L. Bomhoff, B. K. Gorres et al., “Insulin resistance impairs nigrostriatal dopamine function,” Experimental Neurology, vol. 231, no. 1, pp. 171–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. H. Chen, S. M. Zhang, M. A. Hernán, W. C. Willett, and A. Ascherio, “Dietary intakes of fat and risk of Parkinson's disease,” American Journal of Epidemiology, vol. 157, no. 11, pp. 1007–1014, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. W. Hellenbrand, A. Seidler, H. Boeing et al., “Diet and Parkinson's disease I: a possible role for the past intake of specific foods and food groups. Results from a self-administered food- frequency questionnaire in a case-control study,” Neurology, vol. 47, no. 3, pp. 636–643, 1996. View at Publisher · View at Google Scholar · View at Scopus
  130. K. M. Powers, T. Smith-Weller, G. M. Franklin, W. T. Longstreth Jr., P. D. Swanson, and H. Checkoway, “Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes,” Neurology, vol. 60, no. 11, pp. 1761–1766, 2003. View at Publisher · View at Google Scholar · View at Scopus
  131. T. M. da Silva, R. P. Munhoz, C. Alvarez et al., “Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation,” Journal of Affective Disorders, vol. 111, no. 2-3, pp. 351–359, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. F. Kamel, S. M. Goldman, D. M. Umbach et al., “Dietary fat intake, pesticide use, and Parkinson's disease,” Parkinsonism & Related Disorders, vol. 20, no. 1, pp. 82–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. C. Anderson, H. Checkoway, G. M. Franklin, S. Beresford, T. Smith-Weller, and P. D. Swanson, “Dietary factors in Parkinson's disease: the role of food groups and specific foods,” Movement Disorders, vol. 14, no. 1, pp. 21–27, 1999. View at Publisher · View at Google Scholar
  134. J. Dong, J. D. Beard, D. M. Umbach et al., “Dietary fat intake and risk for Parkinson's disease,” Movement Disorders, vol. 29, no. 13, pp. 1623–1630, 2014. View at Google Scholar
  135. A. Oliveira, J. Cacodcar, and D. D. Motghare, “Morbidity among iron ore mine workers in Goa,” Indian Journal of Public Health, vol. 58, no. 1, pp. 57–60, 2014. View at Publisher · View at Google Scholar · View at Scopus
  136. J. A. Mortimer, A. R. Borenstein, and L. M. Nelson, “Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis,” Neurology, vol. 79, no. 11, pp. 1174–1180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Gerlach, D. Ben-Shachar, P. Riederer, and M. B. H. Youdim, “Altered brain metabolism of iron as a cause of neurodegenerative diseases?” Journal of Neurochemistry, vol. 63, no. 3, pp. 793–807, 1994. View at Google Scholar · View at Scopus
  138. J. T. Egaña, C. Zambrano, M. T. Nuñez, C. Gonzalez-Billault, and R. B. Maccioni, “Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures,” BioMetals, vol. 16, no. 1, pp. 215–223, 2003. View at Publisher · View at Google Scholar · View at Scopus
  139. Y. Ke and Z. Ming Qian, “Iron misregulation in the brain: a primary cause of neurodegenerative disorders,” The Lancet Neurology, vol. 2, no. 4, pp. 246–253, 2003. View at Publisher · View at Google Scholar · View at Scopus
  140. L. Zecca, M. B. H. Youdim, P. Riederer, J. R. Connor, and R. R. Crichton, “Iron, brain ageing and neurodegenerative disorders,” Nature Reviews Neuroscience, vol. 5, no. 11, pp. 863–873, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. R. J. Castellani, S. L. Siedlak, G. Perry, and M. A. Smith, “Sequestration of iron by Lewy bodies in Parkinson's disease,” Acta Neuropathologica, vol. 100, no. 2, pp. 111–114, 2000. View at Publisher · View at Google Scholar · View at Scopus
  142. N. Golts, H. Snyder, M. Frasier, C. Theisler, P. Choi, and B. Wolozin, “Magnesium inhibits spontaneous and iron-induced aggregation of α-synuclein,” The Journal of Biological Chemistry, vol. 277, no. 18, pp. 16116–16123, 2002. View at Publisher · View at Google Scholar · View at Scopus
  143. E. C. Hirsch, T. Breidert, E. Rousselet, S. Hunot, A. Hartmann, and P. P. Michel, “The role of glial reaction and inflammation in Parkinson's disease,” Annals of the New York Academy of Sciences, vol. 991, pp. 214–228, 2003. View at Google Scholar · View at Scopus
  144. X. Zhang, N. Surguladze, B. Slagle-Webb, A. Cozzi, and J. R. Connor, “Cellular iron status influences the functional relationship between microglia and oligodendrocytes,” GLIA, vol. 54, no. 8, pp. 795–804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  145. J. Lan and D. H. Jiang, “Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease,” Journal of Neural Transmission, vol. 104, no. 6-7, pp. 649–660, 1997. View at Publisher · View at Google Scholar · View at Scopus
  146. D. Kaur, F. Yantiri, S. Rajagopalan et al., “Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease,” Neuron, vol. 37, no. 6, pp. 899–909, 2003. View at Publisher · View at Google Scholar · View at Scopus
  147. N. Ostrerova-Golts, L. Petrucelli, J. Hardy, J. M. Lee, M. Farer, and B. Wolozin, “The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity,” The Journal of Neuroscience, vol. 20, no. 16, pp. 6048–6054, 2000. View at Google Scholar · View at Scopus
  148. K. M. Erikson, B. C. Jones, and J. L. Beard, “Iron deficiency alters dopamine transporter functioning in rat striatum,” Journal of Nutrition, vol. 130, no. 11, pp. 2831–2837, 2000. View at Google Scholar · View at Scopus
  149. J. Beard, K. M. Erikson, and B. C. Jones, “Neonatal iron deficiency results in irreversible changes in dopamine function in rats,” Journal of Nutrition, vol. 133, no. 4, pp. 1174–1179, 2003. View at Google Scholar · View at Scopus
  150. J. L. Beard, B. Felt, T. Schallert, M. Burhans, J. R. Connor, and M. K. Georgieff, “Moderate iron deficiency in infancy: biology and behavior in young rats,” Behavioural Brain Research, vol. 170, no. 2, pp. 224–232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  151. M. S. Burhans, C. Dailey, J. Wiesinger, L. E. Murray-Kolb, B. C. Jones, and J. L. Beard, “Iron deficiency affects acoustic startle response and latency, but not prepulse inhibition in young adult rats,” Physiology & Behavior, vol. 87, no. 5, pp. 917–924, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. C. W. Levenson, R. G. Cutler, B. Ladenheim, J. L. Cadet, J. Hare, and M. P. Mattson, “Role of dietary iron restriction in a mouse model of Parkinson's disease,” Experimental Neurology, vol. 190, no. 2, pp. 506–514, 2004. View at Publisher · View at Google Scholar · View at Scopus
  153. H. Jiang, Z. Luan, J. Wang, and J. Xie, “Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload,” Neurochemistry International, vol. 49, no. 6, pp. 605–609, 2006. View at Publisher · View at Google Scholar · View at Scopus
  154. G. Logroscino, K. Marder, J. Graziano et al., “Dietary iron, animal fats, and risk of Parkinson's disease,” Movement Disorders, vol. 13, supplement 1, pp. 13–16, 1998. View at Publisher · View at Google Scholar · View at Scopus
  155. H. Checkoway and L. M. Nelson, “Epidemiologic approaches to the study of Parkinson's disease etiology,” Epidemiology, vol. 10, no. 3, pp. 327–336, 1999. View at Publisher · View at Google Scholar · View at Scopus
  156. G. Logroscino, X. Gao, H. Chen, A. Wing, and A. Ascherio, “Dietary iron intake and risk of Parkinson's disease,” The American Journal of Epidemiology, vol. 168, no. 12, pp. 1381–1388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  157. T. Fukushima, X. Tan, Y. Luo, and H. Kanda, “Relationship between blood levels of heavy metals and Parkinson's disease in China,” Neuroepidemiology, vol. 34, no. 1, pp. 18–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  158. C. Borie, F. Gasparini, P. Verpillat et al., “Association study between iron-related genes polymorphisms and Parkinson's disease,” Journal of Neurology, vol. 249, no. 7, pp. 801–804, 2002. View at Publisher · View at Google Scholar · View at Scopus
  159. M. C. J. Dekker, P. C. Giesbergen, O. T. Njajou et al., “Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism,” Neuroscience Letters, vol. 348, no. 2, pp. 117–119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  160. P. G. Mastroberardino, E. K. Hoffman, M. P. Horowitz et al., “A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease,” Neurobiology of Disease, vol. 34, no. 3, pp. 417–431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. A. Takeda, “Manganese action in brain function,” Brain Research Reviews, vol. 41, no. 1, pp. 79–87, 2003. View at Publisher · View at Google Scholar · View at Scopus
  162. J. M. Gorell, C. C. Johnson, B. A. Rybicki et al., “Occupational exposures to metals as risk factors for Parkinson's disease,” Neurology, vol. 48, no. 3, pp. 650–658, 1997. View at Publisher · View at Google Scholar · View at Scopus
  163. M. Williams, G. D. Todd, N. Roney et al., Toxicological Profile for Manganese, Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles, Atlanta, Ga, USA, 2012.
  164. A. C. G. Chua and E. H. Morgan, “Effects of iron deficiency and iron overload on manganese uptake and deposition in the brain and other organs of the rat,” Biological Trace Element Research, vol. 55, no. 1-2, pp. 39–54, 1996. View at Publisher · View at Google Scholar · View at Scopus
  165. N.-E. L. Saris, E. Mervaala, H. Karppanen, J. A. Khawaja, and A. Lewenstam, “Magnesium: an update on physiological, clinical and analytical aspects,” Clinica Chimica Acta, vol. 294, no. 1-2, pp. 1–26, 2000. View at Publisher · View at Google Scholar · View at Scopus
  166. T. Hashimoto, K. Nishi, J. Nagasao, S. Tsuji, and K. Oyanagi, “Magnesium exerts both preventive and ameliorating effects in an in vitro rat Parkinson disease model involving 1-methyl-4-phenylpyridinium (MPP+) toxicity in dopaminergic neurons,” Brain Research, vol. 1197, pp. 143–151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. K. Nakamura, V. P. Bindokas, J. D. Marks et al., “The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited,” Molecular Pharmacology, vol. 58, no. 2, pp. 271–278, 2000. View at Google Scholar · View at Scopus
  168. K. Oyanagi, E. Kawakami, K. Kikuchi-Horie et al., “Magnesium deficiency over generations in rats with special references to the pathogenesis of the parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam,” Neuropathology, vol. 26, no. 2, pp. 115–128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  169. R. Taniguchi, O. Nakagawasai, K. Tan-No et al., “Combined low calcium and lack magnesium is a risk factor for motor deficit in mice,” Bioscience, Biotechnology and Biochemistry, vol. 77, no. 2, pp. 266–270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  170. M. L. Mayer, G. L. Westbrook, and P. B. Buthrie, “Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones,” Nature, vol. 309, no. 5965, pp. 261–263, 1984. View at Publisher · View at Google Scholar · View at Scopus
  171. E. Aden, M. Carlsson, E. Poortvliet et al., “Dietary intake and olfactory function in patients with newly diagnosed parkinson's disease: a case-control study,” Nutritional Neuroscience, vol. 14, no. 1, pp. 25–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  172. N. E. Bharucha, L. Stokes, B. S. Schoenberg et al., “A case-control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors,” Neurology, vol. 36, no. 2, pp. 284–288, 1986. View at Publisher · View at Google Scholar · View at Scopus
  173. F. J. Jimenez-Jimenez, D. Mateo, and S. Gimenez-Roldan, “Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control study,” Movement Disorders, vol. 7, no. 4, pp. 339–344, 1992. View at Publisher · View at Google Scholar · View at Scopus
  174. P. A. Fall, M. Fredrikson, O. Axelson, and A. K. Granerus, “Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden,” Movement Disorders, vol. 14, no. 1, pp. 28–37, 1999. View at Publisher · View at Google Scholar
  175. A. Paganini-Hill, “Risk factors for Parkinson's disease: the Leisure World cohort study,” Neuroepidemiology, vol. 20, no. 2, pp. 118–124, 2001. View at Publisher · View at Google Scholar · View at Scopus
  176. P. Ragonese, G. Salemi, L. Morgante et al., “A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease,” Neuroepidemiology, vol. 22, no. 5, pp. 297–304, 2003. View at Publisher · View at Google Scholar · View at Scopus
  177. A.-K. Eriksson, S. Löfving, R. C. Callaghan, and P. Allebeck, “Alcohol use disorders and risk of Parkinson's disease: findings from a Swedish national cohort study 1972–2008,” BMC Neurology, vol. 13, article no. 190, 2013. View at Publisher · View at Google Scholar · View at Scopus
  178. D. Zhang, H. Jiang, and J. Xie, “Alcohol intake and risk of Parkinson's disease: a meta-analysis of observational studies,” Movement Disorders, vol. 29, no. 6, pp. 819–822, 2014. View at Publisher · View at Google Scholar · View at Scopus
  179. J. S. Felton, M. G. Knize, C. Wood et al., “Isolation and characterization of new mutagens from fried ground beef,” Carcinogenesis, vol. 5, no. 1, pp. 95–102, 1984. View at Publisher · View at Google Scholar · View at Scopus
  180. R. J. Turesky, “Formation and biochemistry of carcinogenic heterocyclic aromatic amines in cooked meats,” Toxicology Letters, vol. 168, no. 3, pp. 219–227, 2007. View at Publisher · View at Google Scholar · View at Scopus
  181. M. Shioya, K. Wakabayashi, S. Sato, M. Nagao, and T. Sugimura, “Formation of a mutagen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine (PhIP) in cooked beef, by heating a mixture containing creatinine, phenylalanine and glucose,” Mutation Research Letters, vol. 191, no. 3-4, pp. 133–138, 1987. View at Publisher · View at Google Scholar · View at Scopus
  182. E. G. Snyderwine, M. H. Buonarati, J. S. Felton, and K. W. Turteltaub, “Metabolism of the food-derived mutagen/carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in nonhuman primates,” Carcinogenesis, vol. 14, no. 12, pp. 2517–2522, 1993. View at Publisher · View at Google Scholar · View at Scopus
  183. J. S. Felton and M. G. Knize, “Occurrence, identification, and bacterial mutagenicity of heterocyclic amines in cooked food,” Mutation Research, vol. 259, no. 3-4, pp. 205–217, 1991. View at Google Scholar · View at Scopus
  184. J. S. Felton, M. G. Knize, R. W. Wu, M. E. Colvin, F. T. Hatch, and M. A. Malfatti, “Mutagenic potency of food-derived heterocyclic amines,” Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis, vol. 616, no. 1-2, pp. 90–94, 2007. View at Publisher · View at Google Scholar · View at Scopus
  185. I. Hiroshi, O. Norio, N. Daiichirou et al., “Effects of heterocyclic amines in food on dopamine metabolism in nigro-striatal dopaminergic neurons,” Biochemical Pharmacology, vol. 37, no. 17, pp. 3289–3295, 1988. View at Publisher · View at Google Scholar · View at Scopus
  186. T. Kojima, M. Naoi, K. Wakabayashi, T. Sugimura, and T. Nagatsu, “3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2) and other heterocyclic amines as inhibitors of mitochondrial monoamine oxidases separated from human brain synaptosomes,” Neurochemistry International, vol. 16, no. 1, pp. 51–57, 1990. View at Google Scholar · View at Scopus
  187. W. Maruyama, A. Ota, A. Takahashi, T. Nagatsu, and M. Naoi, “Food-derived heterocyclic amines, 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole and related amines, as inhibitors of monoamine metabolism,” Journal of Neural Transmission, vol. 41, pp. 327–333, 1994. View at Google Scholar · View at Scopus
  188. M. Ota, M. Naoi, T. Hamanaka, and T. Nagatsu, “Inhibition of human brain aromatic l-amino acid decarboxylase by cooked food-derived 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2) and other heterocyclic amines,” Neuroscience Letters, vol. 116, no. 3, pp. 372–378, 1990. View at Publisher · View at Google Scholar · View at Scopus
  189. J. S. Felton, M. G. Knize, N. H. Shen, B. D. Andresen, L. F. Bjeldanes, and F. T. Hatch, “Identification of the mutagens in cooked beef,” Environmental Health Perspectives, vol. 67, pp. 17–24, 1986. View at Publisher · View at Google Scholar
  190. J. S. Felton, M. G. Knize, N. H. Shen et al., “The isolation and identification of a new mutagen from fried ground beef: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP),” Carcinogenesis, vol. 7, no. 7, pp. 1081–1086, 1986. View at Google Scholar · View at Scopus
  191. S. F. Teunissen, M. L. H. Vlaming, H. Rosing, J. H. M. Schellens, A. H. Schinkel, and J. H. Beijnen, “Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces and eight selected tissues from mice,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 878, no. 25, pp. 2353–2362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  192. A. M. Griggs, Z. S. Agim, V. R. Mishra et al., “2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is selectively toxic to primary dopaminergic neurons in vitro,” Toxicological Sciences, vol. 140, no. 1, pp. 179–189, 2014. View at Publisher · View at Google Scholar
  193. W. Pfau and K. Skog, “Exposure to β-carbolines norharman and harman,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 802, no. 1, pp. 115–126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  194. J. Benito-Leon, F. Bermejo-Pareja, J. M. Morales, S. Vega, and J.-A. Molina, “Prevalence of essential tremor in three elderly populations of central Spain,” Movement Disorders, vol. 18, no. 4, pp. 389–394, 2003. View at Publisher · View at Google Scholar · View at Scopus
  195. O. Dogu, S. Sevim, H. Camdeviren et al., “Prevalence of essential tremor: door-to-door neurologic exams in Mersin Province, Turkey,” Neurology, vol. 61, no. 12, pp. 1804–1806, 2003. View at Publisher · View at Google Scholar · View at Scopus
  196. E. D. Louis, W. Jiang, K. M. Pellegrino et al., “Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor,” NeuroToxicology, vol. 29, no. 2, pp. 294–300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  197. E. D. Louis, P. Factor-Litvak, M. Gerbin et al., “Blood harmane, blood lead, and severity of hand tremor: evidence of additive effects,” NeuroToxicology, vol. 32, no. 2, pp. 227–232, 2011. View at Publisher · View at Google Scholar · View at Scopus
  198. E. D. Louis, M. Michalec, W. Jiang, P. Factor-Litvak, and W. Zheng, “Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson's disease,” NeuroToxicology, vol. 40, pp. 52–56, 2014. View at Publisher · View at Google Scholar · View at Scopus
  199. H. Sienkiewicz-Jarosz, A. Scinska, L. Swiecicki et al., “Sweet liking in patients with Parkinson's disease,” Journal of the Neurological Sciences, vol. 329, no. 1-2, pp. 17–22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  200. H. Miwa and T. Kondo, “Alteration of eating behaviors in patients with Parkinson's disease: Possibly overlooked?” Neurocase, vol. 14, no. 6, pp. 480–484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  201. W. Jiang, C. Ju, H. Jiang, and D. Zhang, “Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies,” European Journal of Epidemiology, vol. 29, no. 9, pp. 613–619, 2014. View at Publisher · View at Google Scholar · View at Scopus
  202. W. C. Willett, F. Sacks, A. Trichopoulou et al., “Mediterranean diet pyramid: a cultural model for healthy eating,” The American Journal of Clinical Nutrition, vol. 61, no. 6, pp. 1402S–1406S, 1995. View at Google Scholar · View at Scopus
  203. R. N. Alcalay, Y. Gu, H. Mejia-Santana, L. Cote, K. S. Marder, and N. Scarmeas, “The association between Mediterranean diet adherence and Parkinson's disease,” Movement Disorders, vol. 27, no. 6, pp. 771–774, 2012. View at Publisher · View at Google Scholar · View at Scopus
  204. N. Yamada-Fowler, M. Fredrikson, and P. Soderkvist, “Caffeine interaction with glutamate receptor gene GRIN2A: Parkinson's disease in Swedish population,” PloS ONE, vol. 9, no. 6, Article ID e99294, 2014. View at Google Scholar
  205. T. H. Hamza, H. Chen, E. M. Hill-Burns et al., “Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a parkinson's disease modifier gene via interaction with coffee,” PLoS Genetics, vol. 7, no. 8, Article ID e1002237, 2011. View at Publisher · View at Google Scholar · View at Scopus